|
1
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United States in 2012-2016. Neuro Oncol. 21 (Suppl
5):v1–v100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
et al: Effect of tumor-treating fields plus maintenance
temozolomide vs maintenance temozolomide alone on survival in
patients with glioblastoma: A randomized clinical trial. JAMA.
318:2306–2316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kargiotis O, Rao JS and Kyritsis AP:
Mechanisms of angiogenesis in gliomas. J Neurooncol. 78:281–293.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Norden AD, Drappatz J and Wen PY:
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol.
5:610–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Plate KH, Scholz A and Dumont DJ: Tumor
angiogenesis and anti-angiogenic therapy in malignant gliomas
revisited. Acta Neuropathol. 124:763–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hundsberger T, Reardon DA and Wen PY:
Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert
Rev Anticancer Ther. 17:507–515. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Masckauchan TN and Kitajewski J:
Wnt/Frizzled signaling in the vasculature: New angiogenic factors
in sight. Physiology (Bethesda). 21:181–188. 2006.PubMed/NCBI
|
|
9
|
Zhang B and Ma JX: Wnt pathway antagonists
and angiogenesis. Protein Cell. 1:898–906. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zerlin M, Julius MA and Kitajewski J:
Wnt/Frizzled signaling in angiogenesis. Angiogenesis. 11:63–69.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Parmalee NL and Kitajewski J: Wnt
signaling in angiogenesis. Curr Drug Targets. 9:558–564. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saitoh T and Katoh M: FRAT1 and FRAT2,
clustered in human chromosome 10q24.1 region, are up-regulated in
gastric cancer. Int J Oncol. 19:311–315. 2001.PubMed/NCBI
|
|
13
|
Jonkers J, Korswagen HC, Acton D, Breuer M
and Berns A: Activation of a novel proto-oncogene, Frat1,
contributes to progression of mouse T-cell lymphomas. EMBO J.
16:441–450. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hagen T, Cross DA, Culbert AA, West A,
Frame S, Morrice N and Reith AD: FRAT1, a substrate-specific
regulator of glycogen synthase kinase-3 activity, is a cellular
substrate of protein kinase A. J Biol Chem. 281:35021–35029. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ferkey DM and Kimelman D: Glycogen
synthase kinase-3 beta mutagenesis identifies a common binding
domain for GBP and Axin. J Biol Chem. 277:16147–16152. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yost C, Farr GH III, Pierce SB, Ferkey DM,
Chen MM and Kimelman D: GBP, an inhibitor of GSK-3, is implicated
in Xenopus development and oncogenesis. Cell. 93:1031–1041. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Yu JH, Lin XY, Miao Y, Han Y, Fan
CF, Dong XJ, Dai SD and Wang EH: Overexpression of Frat1 correlates
with malignant phenotype and advanced stage in human non-small cell
lung cancer. Virchows Arch. 459:255–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Hewitt SM, Liu S, Zhou X, Zhu H,
Zhou C, Zhang G, Quan L, Bai J and Xu N: Tissue microarray analysis
of human FRAT1 expression and its correlation with the subcellular
localisation of beta-catenin in ovarian tumours. Br J Cancer.
94:686–691. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu K, Guo J, Wang H and Yu W: FRAT1
expression regulates proliferation in colon cancer cells. Oncol
Lett. 12:4761–4766. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Liu S, Zhu H, Zhang W, Zhang G,
Zhou X, Zhou C, Quan L, Bai J, Xue L, et al: FRAT1 overexpression
leads to aberrant activation of beta-catenin/TCF pathway in
esophageal squamous cell carcinoma. Int J Cancer. 123:561–568.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo G, Zhong CL, Liu Y, Mao XG, Zhang Z,
Jin J, Liu J, Yang L, Mao JM, Guo YH and Zhao YL: Overexpression of
FRAT1 is associated with malignant phenotype and poor prognosis in
human gliomas. Dis Markers. 2015:2897502015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-Seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding J, Liang Z, Feng W, Cai Q and Zhang
Z: Integrated bioinformatics analysis reveals potential pathway
biomarkers and their interactions for clubfoot. Med Sci Monit.
26:e9252492020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Subramanian A, Kuehn H, Gould J, Tamayo P
and Mesirov JP: GSEA-P: A desktop application for gene set
enrichment analysis. Bioinformatics. 23:3251–3253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo G, Kuai D, Cai S, Xue N, Liu Y, Hao J,
Fan Y, Jin J, Mao X, Liu B, et al: Knockdown of FRAT1 expression by
RNA interference inhibits human glioblastoma cell growth, migration
and invasion. PLoS One. 8:e612062013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Robinson RL, Sharma A, Bai S, Heneidi S,
Lee TJ, Kodeboyina SK, Patel N and Sharma S: Comparative
STAT3-regulated gene expression profile in renal cell carcinoma
subtypes. Front Oncol. 9:722019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Onishi M, Ichikawa T, Kurozumi K and Date
I: Angiogenesis and invasion in glioma. Brain Tumor Pathol.
28:13–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cea V, Sala C and Verpelli C:
Antiangiogenic therapy for glioma. J Signal Transduct.
2012:4830402012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chi AS, Sorensen AG, Jain RK and Batchelor
TT: Angiogenesis as a therapeutic target in malignant gliomas.
Oncologist. 14:621–636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Irizarry LR, Hambardzumyan D, Nakano I,
Gladson CL and Ahluwalia MS: Therapeutic targeting of VEGF in the
treatment of glioblastoma. Expert Opin Ther Targets. 16:973–984.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Macdonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y, Han Y, Zheng R, Yu JH, Miao Y,
Wang L and Wang EH: Expression of Frat1 correlates with expression
of beta-catenin and is associated with a poor clinical outcome in
human SCC and AC. Tumour Biol. 33:1437–1444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He L, Yang Z, Zhou J and Wang W: The
clinical pathological significance of FRAT1 and ROR2 expression in
cartilage tumors. Clin Transl Oncol. 17:438–445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo G, Mao X, Wang P, Liu B, Zhang X,
Jiang X, Zhong C, Huo J, Jin J and Zhuo Y: The expression profile
of FRAT1 in human gliomas. Brain Res. 1320:152–158. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo G, Liu B, Zhong C, Zhang X, Mao X,
Wang P, Jiang X, Huo J, Jin J, Liu X and Chen X: FRAT1 expression
and its correlation with pathologic grade, proliferation, and
apoptosis in human astrocytomas. Med Oncol. 28:1–6. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nager M, Bhardwaj D, Cantí C, Medina L,
Nogués P and Herreros J: β-catenin signalling in glioblastoma
multiforme and glioma-initiating cells. Chemother Res Pract.
2012:1923622012.PubMed/NCBI
|
|
43
|
Dajani R, Fraser E, Roe SM, Yeo M, Good
VM, Thompson V, Dale TC and Pearl LH: Structural basis for
recruitment of glycogen synthase kinase 3beta to the axin-APC
scaffold complex. EMBO J. 22:494–501. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jamieson C, Sharma M and Henderson BR: Wnt
signaling from membrane to nucleus: β-catenin caught in a loop. Int
J Biochem Cell Biol. 44:847–850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sareddy GR, Panigrahi M, Challa S,
Mahadevan A and Babu PP: Activation of Wnt/beta-catenin/Tcf
signaling pathway in human astrocytomas. Neurochem Int. 55:307–317.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu Q, Shang LU, Yu H, Yang Z and Xu D:
Silencing of FRAT1 by siRNA inhibits the proliferation of SGC7901
human gastric adenocarcinoma cells. Biomed Rep. 4:223–226. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zheng K, Zhou X, Yu J, Li Q, Wang H, Li M,
Shao Z, Zhang F, Luo Y, Shen Z, et al: Epigenetic silencing of
miR-490-3p promotes development of an aggressive colorectal cancer
phenotype through activation of the Wnt/β-catenin signaling
pathway. Cancer Lett. 376:178–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fan WH, Du FJ, Liu XJ and Chen N:
Knockdown of FRAT1 inhibits hypoxia-induced
epithelial-to-mesenchymal transition via suppression of the
Wnt/β-catenin pathway in hepatocellular carcinoma cells. Oncol Rep.
36:2999–3004. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Guo G, Liu J, Ren Y, Mao X, Hao Y, Zhong
C, Chen X, Wang X, Wu Y, Lian S, et al: FRAT1 enhances the
proliferation and tumorigenesis of CD133(+)Nestin(+) glioma stem
cells in vitro and in vivo. J Cancer. 11:2421–2430. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hu J, Dong A, Fernandez-Ruiz V, Shan J,
Kawa M, Martínez-Ansó E, Prieto J and Qian C: Blockade of Wnt
signaling inhibits angiogenesis and tumor growth in hepatocellular
carcinoma. Cancer Res. 69:6951–6959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen Y, Hu Y, Lu K, Flannery JG and Ma JX:
Very low-density lipoprotein receptor, a negative regulator of the
wnt signaling pathway and choroidal neovascularization. J Biol
Chem. 282:34420–34428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kazanskaya O, Ohkawara B, Heroult M, Wu W,
Maltry N, Augustin HG and Niehrs C: The Wnt signaling regulator
R-spondin 3 promotes angioblast and vascular development.
Development. 135:3655–3664. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang X, Gaspard JP and Chung DC:
Regulation of vascular endothelial growth factor by the Wnt and
K-ras pathways in colonic neoplasia. Cancer Res. 61:6050–6054.
2001.PubMed/NCBI
|
|
54
|
Easwaran V, Lee SH, Inge L, Guo L,
Goldbeck C, Garrett E, Wiesmann M, Garcia PD, Fuller JH, Chan V, et
al: beta-Catenin regulates vascular endothelial growth factor
expression in colon cancer. Cancer Res. 63:3145–3153.
2003.PubMed/NCBI
|
|
55
|
Hsieh M, Boerboom D, Shimada M, Lo Y,
Parlow AF, Luhmann UFO, Berger W and Richards JS: Mice null for
frizzled4 (Fzd4-/-) are infertile and exhibit impaired corpora
lutea formation and function. Biol Reprod. 73:1135–1146. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Du J and Li J: The role of wnt signaling
pathway in atherosclerosis and its relationship with angiogenesis.
Exp Ther Med. 16:1975–1981. 2018.PubMed/NCBI
|
|
57
|
Kim JW, Gao P, Liu YC, Semenza GL and Dang
CV: Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively
induce vascular endothelial growth factor and metabolic switches
hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol.
27:7381–7393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Skurk C, Maatz H, Rocnik E, Bialik A,
Force T and Walsh K: Glycogen-Synthase Kinase3beta/beta-catenin
axis promotes angiogenesis through activation of vascular
endothelial growth factor signaling in endothelial cells. Circ Res.
96:308–318. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Guo S, Arai K, Stins MF, Chuang DM and Lo
EH: Lithium upregulates vascular endothelial growth factor in brain
endothelial cells and astrocytes. Stroke. 40:652–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhao P, Li Q, Shi Z, Li C, Wang L, Liu X,
Jiang C, Qian X, You Y, Liu N, et al: GSK-3beta regulates tumor
growth and angiogenesis in human glioma cells. Oncotarget.
6:31901–31915. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Vallée A, Guillevin R and Vallée JN:
Vasculogenesis and angiogenesis initiation under normoxic
conditions through Wnt/β-catenin pathway in gliomas. Rev Neurosci.
29:71–91. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Xiao SF, Tang HR, Bai Y, Zou RC, Ren ZF,
Wu XS, Shi ZT, Lan S, Liu W, Wu TG, et al: Swertiamarin suppresses
proliferation, migration, and invasion of hepatocellular carcinoma
cells via negative regulation of FRAT1. Eur J Histochem.
64:271–278. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Tian W, Lei N, Guo R, Yuan Z and Chang L:
Long non-coding RNA DANCR promotes cervical cancer growth via
activation of the Wnt/β-catenin signaling pathway. Cancer Cell Int.
20:612020. View Article : Google Scholar : PubMed/NCBI
|
